Lord, Abbett & Co
GEVA

Lord, Abbett & Co’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Lord, Abbett & Co’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-388,980
Closed -$37.9M – 1037
2015
Q1 		$37.9M Sell
388,980
-44,062
-10% -$4.66M 0.1% 330
2014
Q4 		$40.2M Sell
433,042
-23,505
-5% -$1.85M 0.1% 281
2014
Q3 		$31.4M Sell
456,547
-41,278
-8% -$2.96M 0.08% 357
2014
Q2 		$52.2M Buy
497,825
+144,140
+41% +$12.3M 0.12% 237
2014
Q1 		$29.3M Sell
353,685
-152,938
-30% -$14.1M 0.07% 413
2013
Q4 		$32.8M Buy
506,623
+79,029
+18% +$4.69M 0.07% 394
2013
Q3 		$27.1M Buy
427,594
+251,616
+143% +$12.4M 0.06% 442
2013
Q2 		$7.39M Buy
+175,978
New +$8.02M 0.02% 696

Lord, Abbett & Co's GEVA Position: Q2 2015 in Review

Lord, Abbett & Co sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 388,980 shares — an estimated $37.9M sold.

Lord, Abbett & Co first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $52.2M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Lord, Abbett & Co reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 388,980 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $37.9M.
  • Lord, Abbett & Co first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Lord, Abbett & Co's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $52.2M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.